% alzhub.org library filter
% Source: https://alzhub.org/research?author=Lu+M&about=clinical-trials
% 15 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2025-40390253,
  author  = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others},
  title   = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.70293},
  pmid    = {40390253},
  url     = {https://doi.org/10.1002/alz.70293}
}

@article{zimmer2025-40063015,
  author  = {Zimmer, J. A. and Ardayfio, P. and Wang, H. and Khanna, R. and Evans, C. D. and Lu, M. and Sparks, J. and Andersen, S. and Lauzon, S. and Nery, E. S. M. and others},
  title   = {{Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials}},
  journal = {JAMA Neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.0065},
  pmid    = {40063015},
  url     = {https://doi.org/10.1001/jamaneurol.2025.0065}
}

@article{pontecorvo2022-36251300,
  author  = {Pontecorvo, M. J. and Lu, M. and Burnham, S. C. and Schade, A. E. and Dage, J. L. and Shcherbinin, S. and Collins, E. C. and Sims, JR. and others},
  title   = {{Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.3392},
  pmid    = {36251300},
  url     = {https://doi.org/10.1001/jamaneurol.2022.3392}
}

@article{salloway2018-30129411,
  author  = {Salloway, S. and Marshall, G. A. and Lu, M. and Brashear, H. R.},
  title   = {{Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study}},
  journal = {Current Alzheimer research},
  year    = {2018},
  doi     = {10.2174/1567205015666180821114813},
  pmid    = {30129411},
  url     = {https://doi.org/10.2174/1567205015666180821114813}
}

@article{lu2021-33587110,
  author  = {Lu, M. and Pontecorvo, M. J. and Devous, M. D. and Arora, A. K. and Galante, N. and McGeehan, A. and Devadanam, C. and Salloway, S. P. and others},
  title   = {{Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials}},
  journal = {JAMA neurology},
  year    = {2021},
  doi     = {10.1001/jamaneurol.2020.5505},
  pmid    = {33587110},
  url     = {https://doi.org/10.1001/jamaneurol.2020.5505}
}

@article{lu2025-41082199,
  author  = {Lu, M. and Kim, M. J. and Collins, E. C. and Shcherbinin, S. and Ellinwood, A. K. and Yokoi, Y. and Brooks, D. A. and Hansson, O. and others},
  title   = {{Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.3869},
  pmid    = {41082199},
  url     = {https://doi.org/10.1001/jamaneurol.2025.3869}
}

@article{shcherbinin2022-36094645,
  author  = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others},
  title   = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2793},
  pmid    = {36094645},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2793}
}

@article{sims2023-9857475c,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

@article{sims2023-37459141,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and others},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}

@article{delnomdedieu2016-26925577,
  author  = {Delnomdedieu, M. and Duvvuri, S. and Li, D. J. and Atassi, N. and Lu, M. and Brashear, H. R. and Liu, E. and Ness, S. and others},
  title   = {{First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2016},
  doi     = {10.1186/s13195-016-0177-y},
  pmid    = {26925577},
  url     = {https://doi.org/10.1186/s13195-016-0177-y}
}

@article{atri2026-42128444,
  author  = {Atri, A. and Apostolova, L. G. and Iwata, A. and Wessels, A. M. and Atkins, A. and Lu, M. and Ye, W. and Ryan, S. and Doty, E. G.},
  title   = {{Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial}},
  journal = {Neurology: Clinical Practice},
  year    = {2026},
  doi     = {10.1212/CPJ.0000000000200621},
  pmid    = {42128444},
  url     = {https://doi.org/10.1212/CPJ.0000000000200621}
}

@article{brody2016-27589523,
  author  = {Brody, M. and Liu, E. and Di, J. and Lu, M. and Margolin, R. A. and Werth, J. L. and Booth, K. and Shadman, A. and others},
  title   = {{A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2016},
  doi     = {10.3233/jad-160369},
  pmid    = {27589523},
  url     = {https://doi.org/10.3233/jad-160369}
}

@article{lo2021-34113788,
  author  = {Lo, A. C. and Evans, C. D. and Mancini, M. and Wang, H. and Shcherbinin, S. and Lu, M. and Natanegara, F. and Willis, B. A.},
  title   = {{Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia}},
  journal = {Journal of Alzheimer's disease reports},
  year    = {2021},
  doi     = {10.3233/adr-210296},
  pmid    = {34113788},
  url     = {https://doi.org/10.3233/adr-210296}
}

@article{collins2026-42565262,
  author  = {Collins, E. C. and Lu, M. and Beck, R. and Hendrix, J. and Hodsdon, M. E. and Hansson, O.},
  title   = {{Plasma P-tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease}},
  journal = {Alzheimer's \& Dementia},
  year    = {2026},
  doi     = {10.1002/alz.71740},
  pmid    = {42565262},
  url     = {https://doi.org/10.1002/alz.71740}
}

@article{ketter2016-29199321,
  author  = {Ketter, N. and Liu, E. and Di, J. and Honig, L. S. and Lu, M. and Novak, G. and Werth, J. and LePrince Leterme, G. and others},
  title   = {{A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2016},
  doi     = {10.14283/jpad.2016.118},
  pmid    = {29199321},
  url     = {https://doi.org/10.14283/jpad.2016.118}
}